Literature DB >> 14739679

Neonatal screening for cystic fibrosis: France rises to the challenge.

J P Farriaux1, M Vidailhet, M L Briard, V Belot, J L Dhondt.   

Abstract

This paper describes the adjustments to the French neonatal screening programme required by the introduction of systematic screening for cystic fibrosis (CF), taking into account both the legal and statutory framework and the lessons of a pilot study carried out 10 years ago. The French association for the screening and prevention of infant handicaps (AFDPHE) has been mandated by its regulatory agencies to organize screening for CF in France (metropolitan and overseas territories). During the year 2001, expert groups (Technical Aspects, Information, Ethics and Genetics, Criteria for CF Centres, Protocol for the Care of a Newborn with CF) issued recommendations for the establishment of a national programme that would guarantee efficiency and adequate patient care from the time of diagnosis onward. The programme is based on a strategy combining immunoreactive trypsin (IRT) assay and the analysis of DNA mutations in dried blood samples obtained at 3 days of age. When an elevated IRT value is found, DNA analysis is performed on the same sample. Owing to the relative regional heterogeneity existing in France, 30 selected mutations are used, which provide 85% coverage. The Ethics and Genetics Committee recommended that, in order to avoid arousing anxiety by a recall, informed consent, according to the French legislation on bioethics, should be obtained for all neonates at birth by having the parents sign directly on the sampling paper. Information brochures for parents and health professionals have been designed. A new organization of patient care, involving the creation of CF centres recognized by the Ministry of Health, has been decided; all children diagnosed are to be referred to such centres, where they can be well cared for by a trained staff with sufficient means. The programme was implemented region by region in France, from the beginning of the year 2002 to early 2003. The expert groups still meet periodically to evaluate the implementation of the programme and to check that the terms of the agreement between the AFDPHE and the Social Security Agency are complied with.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14739679     DOI: 10.1023/B:BOLI.0000009921.42503.c2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  10 in total

1.  [Molecular genetics: pre- and post-analytic "best practices"].

Authors:  D Duchassaing; B Dingeon; J Chalas; M Coude; M P Coulhon; J M Launay
Journal:  Ann Biol Clin (Paris)       Date:  2002 Sep-Oct       Impact factor: 0.459

Review 2.  Neonatal screening for inborn errors of metabolism: cost, yield and outcome.

Authors:  R J Pollitt; A Green; C J McCabe; A Booth; N J Cooper; J V Leonard; J Nicholl; P Nicholson; J R Tunaley; N K Virdi
Journal:  Health Technol Assess       Date:  1997       Impact factor: 4.014

3.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

4.  [Genetic testing for cystic fibrosis: evaluation of the Elucigene CF20 kit in blood and buccal cells].

Authors:  D Feldmann; C Guittard; M D Georges; C Houdayer; C Magnier; M Claustres; R Couderc
Journal:  Ann Biol Clin (Paris)       Date:  2001 May-Jun       Impact factor: 0.459

5.  Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.

Authors:  E Ranieri; R G Ryall; C P Morris; P V Nelson; W F Carey; A C Pollard; E F Robertson
Journal:  BMJ       Date:  1991-05-25

6.  Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing.

Authors:  A Tluczek; E H Mischler; P M Farrell; N Fost; N M Peterson; P Carey; W T Bruns; C McCarthy
Journal:  J Dev Behav Pediatr       Date:  1992-06       Impact factor: 2.225

7.  Reduced morbidity in patients with cystic fibrosis detected by neonatal screening.

Authors:  B Wilcken; G Chalmers
Journal:  Lancet       Date:  1985-12-14       Impact factor: 79.321

8.  Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.

Authors:  C Corbetta; M Seia; A Bassotti; A Ambrosioni; A Giunta; R Padoan
Journal:  J Med Screen       Date:  2002       Impact factor: 2.136

9.  Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis.

Authors:  L N al-Jader; M C Goodchild; H C Ryley; P S Harper
Journal:  Clin Genet       Date:  1990-12       Impact factor: 4.438

10.  Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.

Authors:  C Férec; C Verlingue; P Parent; J F Morin; J P Codet; G Rault; M Dagorne; A Lemoigne; H Journel; M Roussey
Journal:  Hum Genet       Date:  1995-11       Impact factor: 4.132

  10 in total
  4 in total

1.  False-positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): Should we adjust IRT cut-off to ethnic origin?

Authors:  D Cheillan; M Vercherat; F Chevalier-Porst; M Charcosset; M O Rolland; C Dorche
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Neonatal screening: from the 'Guthrie age' to the 'genetic age'.

Authors:  Jean-Louis Dhondt
Journal:  J Inherit Metab Dis       Date:  2007-05-12       Impact factor: 4.982

3.  Differences in immunoreactive trypsin values between type of feeding and ethnicity in neonatal cystic fibrosis screening: a cross-sectional study.

Authors:  Ernesto Cortés; Ana María Roldán; Antonio Palazón-Bru; María Mercedes Rizo-Baeza; Herminia Manero; Vicente Francisco Gil-Guillén
Journal:  Orphanet J Rare Dis       Date:  2014-11-07       Impact factor: 4.123

4.  Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy.

Authors:  Marie Pierre Audrézet; Anne Munck; Virginie Scotet; Mireille Claustres; Michel Roussey; Dominique Delmas; Claude Férec; Marie Desgeorges
Journal:  Genet Med       Date:  2014-08-14       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.